STTK - NASDAQ
Shattuck Labs, Inc.
$4.89
+0.43%Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
At a Glance
Live SnapshotShattuck Labs, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Shattuck Labs, Inc. Balance Sheet
STTK • NASDAQ
| Shattuck Labs, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
54.2M | 57.4M | 125.6M | 47.4M | 92.3M | 157.9M | 7M | 31.6M | |
23.9M | 15.6M | 5M | 113.9M | 176.5M | 177.6M | 32.1M | 28.7M | |
78.1M | 73M | 130.6M | 161.3M | 268.8M | 335.4M | 39.1M | 60.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 19.5M | 10.2M | 3.4M | 5.3M | |
4.4M | 6.2M | 12.6M | 23.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
82.5M | 79.2M | 143.2M | 184.6M | 288.3M | 345.6M | 42.4M | 65.6M | |
NON-CURRENT ASSETS | ||||||||
6.1M | 9.8M | 13.8M | 17.7M | 9.9M | 3M | 2.4M | 2.5M | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.4M | 2M | 2.5M | 3.1M | 381K | 349K | 90K | 23K | |
8.6M | 11.8M | 16.3M | 20.7M | 10.3M | 3.3M | 2.5M | 2.5M | |
91M | 91M | 159.6M | 205.3M | 298.6M | 349M | 45M | 68.2M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
2.1M | 2.4M | 1.6M | 7.2M | 10M | 1.8M | 3.1M | 2M | |
2.1M | 2.4M | 1.6M | 7.2M | 10M | 1.8M | 3.1M | 2M | |
0.0 | 0.0 | 4.2M | 11.3M | 3.3M | 1.6M | 966K | 777K | |
0.0 | 900K | 796K | 701K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.7M | 12.9M | 17M | |
5M | 5.6M | 4.8M | 5.8M | 11.3M | 5.8M | 3.1M | 983K | |
7.1M | 8.9M | 11.5M | 25M | 24.6M | 16.8M | 20M | 20.9M | |
NON-CURRENT LIABILITIES | ||||||||
1.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.3M | 9.6M | 8.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 2.2M | 987K | 50M | 50M | |
1.6M | 2.5M | 3.4M | 4.2M | 2.2M | 22.3M | 59.5M | 58.4M | |
0.0 | 3.4M | 4.2M | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
8.6M | 11.4M | 14.9M | 29.2M | 26.8M | 39.1M | 79.5M | 79.2M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -887K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49.1M | 49.1M | |
7K | 5K | 5K | 5K | 5K | 5K | 1K | 1K | |
512.9M | 461.3M | 451M | 396M | 389.4M | 382M | 887K | 426K | |
-430.5M | -381.7M | -306.3M | -219M | -117.1M | -72.1M | -35.5M | -11.5M | |
6K | 2K | 4K | -877K | -560K | -63K | 54K | -49.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -48.2M | 1K | |
82.4M | 79.6M | 144.7M | 176.2M | 271.8M | 309.9M | -34.5M | -11.1M | |
82.4M | 79.6M | 144.7M | 176.2M | 271.8M | 309.9M | -34.5M | -11.1M | |
SUMMARY | ||||||||
91M | 91M | 159.6M | 205.3M | 298.6M | 349M | 45M | 68.2M | |
24.9M | 15.6M | 5M | 113.9M | 176.5M | 177.6M | 32.1M | 28.7M | |
1.6M | 3.4M | 4.2M | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
-52.6M | -54M | -121.4M | -42.5M | -92.3M | -157.9M | -7M | -31.6M | |
47,903,215 | 47,903,215 | 47,903,215 | 47,903,215 | 47,903,215 | 47,903,215 | 47,903,215 | 47,903,215 |
SEC Filings
STTK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 22, 2026 | 2026 | |
S-3 S-3 N/A | January 13, 2026 | January 13, 2026 | ||
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your STTK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.